Anticancer Potential of Metformin: Focusing on Gastrointestinal Cancers

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2021 Mar 21

PMID 33744985

Citations 5

Authors

Mohammad Rafi Khezri

Hassan Malekinejad

Naime Majidi-Zolbanin

Morteza Ghasemnejad-Berenji

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal cancers are one of the most common types of cancer that have high annual mortality; therefore, identification and introduction of safe drugs in the control and prevention of these cancers are of particular importance. Metformin, a lipophilic biguanide, is the most commonly prescribed agent for type 2 diabetes management. In addition to its great effects on lowering the blood glucose concentrations, the anti-cancer properties of this drug have been reported in many types of cancers such as gastrointestinal cancers. Hence the effects of this agent as a safe drug on the reduction of gastrointestinal cancer risk and suppression of these types of cancers have been studied in different clinical trials. Furthermore, the proposed mechanisms of metformin in preventing the growth of these cancers have been investigated in several studies. In this review, we discuss recent advances in elucidating the molecular mechanisms that are relevant for metformin use in gastrointestinal cancer treatment.

Citing Articles

Metformin alleviates doxorubicin-induced hepatic damage by modulating oxidative stress: a molecular, biochemical, and histopathological approach in a rat model.

Lal-Shahsavar S, Zolbanin N, Jafari A, Ghasemnejad-Berenji M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39903256 DOI: 10.1007/s00210-024-03688-2.

The role of microbiomes in gastrointestinal cancers: new insights.

Yarahmadi A, Afkhami H Front Oncol. 2024; 13:1344328.

PMID: 38361500 PMC: 10867565. DOI: 10.3389/fonc.2023.1344328.

Predictors of gastrointestinal complaints in patients on metformin therapy.

Raicevic B, Jankovic S Open Med (Wars). 2023; 18(1):20230871.

PMID: 38045859 PMC: 10693010. DOI: 10.1515/med-2023-0871.

Autophagy in gastrointestinal cancers.

Shao B, Chai N, Yao Y, Li J, Law H, Linghu E Front Oncol. 2022; 12:975758.

PMID: 36091106 PMC: 9459114. DOI: 10.3389/fonc.2022.975758.

The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.

Gulla A, Andriusaityte U, Zdanys G, Babonaite E, Strupas K, Kelly H Medicina (Kaunas). 2022; 58(4).

PMID: 35454306 PMC: 9032206. DOI: 10.3390/medicina58040467.

References

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A . Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-5. PMC: 558205. DOI: 10.1136/bmj.38415.708634.F7. View

Shaw R, Lamia K, Vasquez D, Koo S, Bardeesy N, DePinho R . The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310(5754):1642-6. PMC: 3074427. DOI: 10.1126/science.1120781. View

Engelman J, Luo J, Cantley L . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-19. DOI: 10.1038/nrg1879. View

Tang C, Lu Y, Xie J, Wang F, Zou J, Yang J . Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs. 2009; 20(4):249-58. DOI: 10.1097/CAD.0b013e328327d476. View

Cardone M, Roy N, Stennicke H, Salvesen G, Franke T, Stanbridge E . Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998; 282(5392):1318-21. DOI: 10.1126/science.282.5392.1318. View

Masuyama N, Oishi K, Mori Y, Ueno T, Takahama Y, Gotoh Y . Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem. 2001; 276(35):32799-805. DOI: 10.1074/jbc.M105431200. View

Brunet A, Bonni A, Zigmond M, Lin M, Juo P, Hu L . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96(6):857-68. DOI: 10.1016/s0092-8674(00)80595-4. View

Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y . Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91(2):231-41. DOI: 10.1016/s0092-8674(00)80405-5. View

10.

Wilson B, Mochon E, Boxer L . Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 1996; 16(10):5546-56. PMC: 231554. DOI: 10.1128/MCB.16.10.5546. View

11.

Pugazhenthi S, Nesterova A, Sable C, Heidenreich K, Boxer L, Heasley L . Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2001; 275(15):10761-6. DOI: 10.1074/jbc.275.15.10761. View

12.

Du K, Montminy M . CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998; 273(49):32377-9. DOI: 10.1074/jbc.273.49.32377. View

13.

Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K . ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001; 2(3):222-8. PMC: 1083842. DOI: 10.1093/embo-reports/kve046. View

14.

Yamamoto K, Ichijo H, Korsmeyer S . BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 1999; 19(12):8469-78. PMC: 84954. DOI: 10.1128/MCB.19.12.8469. View

15.

Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C . Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem. 1997; 272(40):25238-42. DOI: 10.1074/jbc.272.40.25238. View

16.

Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui T . JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell. 2004; 13(3):329-40. DOI: 10.1016/s1097-2765(04)00028-0. View

17.

An D, Kewalramani G, Chan J, Qi D, Ghosh S, Pulinilkunnil T . Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia. 2006; 49(9):2174-84. DOI: 10.1007/s00125-006-0338-9. View

18.

Jang J, Song I, Sung E, Lee T, Kim J . Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells. Oncol Lett. 2018; 16(2):2030-2038. PMC: 6036402. DOI: 10.3892/ol.2018.8832. View

19.

Wu N, Gu C, Gu H, Hu H, Han Y, Li Q . Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 2011; 58(6):482-90. DOI: 10.4149/neo_2011_06_482. View

20.

Dawson D, Volpert O, Gillis P, Crawford S, Xu H, BENEDICT W . Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999; 285(5425):245-8. DOI: 10.1126/science.285.5425.245. View